Filing identity and period
Important discrepancy: The supplied filing is Helius Medical Technologies, Inc.’s Form 10-Q, not a filing for Solana Co. It reports the three and six months ended June 30, 2021; the filing was signed August 12, 2021. Financial amounts below are in U.S. dollars unless stated otherwise.
Business context
Helius develops the PoNS non-invasive neuromodulation device. PoNS was commercially available in Canada, where COVID-19 restrictions and clinic capacity affected sales. The FDA authorized PoNS in March 2021 for a specified multiple-sclerosis-related gait-deficit indication, but the company did not expect U.S. commercial availability before the first quarter of 2022. The mmTBI clinical trial, TBI-002, was suspended while the company evaluated funding and timing.
Financial results and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $71,000 | $133,000 | $155,000 | $339,000 |
| Gross profit | $4,000 | $69,000 | $72,000 | $174,000 |
| Operating loss | $(6.166) million | $(3.722) million | $(9.667) million | $(7.724) million |
| Net loss | $(5.981) million | $(3.361) million | $(9.343) million | $(8.118) million |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $(6.690) million | $(6.979) million |
Q2 gross margin was approximately 5.6% ($4,000 gross profit on $71,000 revenue); six-month gross margin was approximately 46.5%. These figures include license revenue as well as product sales. Product sales fell 50% in Q2 and about 56% for the first half year over year. Management attributed the decline to COVID-related clinic limits and pricing changes intended to reduce upfront costs.
Q2 SG&A rose to $4.744 million from $2.394 million, primarily due to higher stock-based compensation and legal and professional fees. The increase included approximately $1.0 million for a one-time, fully vested option award to the then interim CEO. First-half R&D was $2.694 million, up from $2.428 million; SG&A was $6.939 million, up from $5.255 million.
At June 30, cash was $7.425 million, compared with $3.331 million at December 31, 2020; working capital was $6.848 million, compared with $2.261 million. Total liabilities were $2.350 million, including $62,000 of current lease liability; the filing reports no borrowings under debt financing at period end. First-half financing cash flow was $10.834 million, mainly from the February 2021 equity-and-warrant offering and warrant exercises. The company reported 2,317,772 common shares outstanding at June 30, versus 1,484,362 at year-end.
Material changes, outlook and risks
- The six-month net loss widened by $1.225 million year over year despite lower operating cash use; higher operating expenses were partly offset by a more favorable foreign-exchange result.
- The company stated that existing resources, based on the first-half cash-burn rate, were expected to fund operations into the first quarter of 2022. It also expected spending to rise for U.S. pre-commercialization, manufacturing and product work, personnel, and possible clinical trials or regulatory efforts. Additional financing may be needed; management gave no revenue or earnings guidance.
- The filing says substantial doubt exists about the company’s ability to continue as a going concern within one year after filing. It warns that financing may not be available on acceptable terms and that operations could be reduced or wound down if funds are insufficient.
- COVID-19 could continue to constrain Canadian clinic activity, patient participation, clinical programs, suppliers, regulatory work and capital access. The Medicare Coverage of Innovative Technology pathway was delayed until December 15, 2021, and the company was assessing implications for reimbursement.
- The company recorded $324,000 of first-half foreign-exchange gain, compared with a $460,000 loss in the prior-year period. It recorded no impairment of goodwill at June 30 after a triggering-event assessment. No material legal proceedings were reported.
- After quarter end, the company adopted a 100,000-share inducement plan. It also disclosed that its COO’s employment ended July 20, 2021; separation terms were not finalized as of August 12.
Investor verification priorities
- Confirm the issuer identity: this source is Helius Medical Technologies, Inc., not Solana Co.
- Review the going-concern disclosure, cash runway assumptions and financing needs against subsequent filings and cash use.
- Track U.S. launch timing, reimbursement plans, and whether the CMS pathway delay or other regulatory developments affect commercialization.
- Assess Canadian sales, clinic capacity, pricing and payer reimbursement progress against the company’s stated COVID-related constraints.
- Review dilution from equity offerings, warrants, options and compensation awards, including the increase in shares outstanding.